SEC Form 4 · accession 0001209191-19-018817
Intellia Therapeutics, Inc. · NTLA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Andrew Schiermeier
Officer — EVP, Dev and Corp Strategy
Period of report
Mar 6, 2019
Accepted (ET)
Mar 12, 2019 · 4:38 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001652130
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 6, 2019 | P | 3,250 | $16.00 | A | 3,250 | D | |
| Common Stock | Mar 6, 2019 | P | 4,250 | $15.50 | A | 7,500 | D | |
| Common StockF1 | holding | — | — | — | 8,644 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Includes 1,091 and 53 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on June 30, 2018 and December 31, 2018, respectively.